OncoMatch/Clinical Trials/NCT06817525
Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC
Is NCT06817525 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including 6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 (d 1) and 6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 (d 1) for triple-negative breast cancer.
Treatment: 6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 (d 1) · 6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 (d 1) — We plan to explore the efficacy and safety of albumin-bound paclitaxel+carboplatin+Camrelizumab in neoadjuvant therapy for early TNBC patients, optimize the administration method and drug combination therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) negative (ihc 0, 1+ without fish, or ihc 2+ without fish amplification)
Required: ESR1 negative (ihc nuclear staining <10%)
Required: PR (PGR) negative (ihc nuclear staining <10%)
Disease stage
Required: Stage CT4B, CT4C, CT4D, CT1C WITH AXILLARY LYMPH NODE METASTASIS (TNM)
Excluded: Stage IV
cT2- cT4d, or cT1c with axillary lymph node metastasis; There is evidence of metastatic breast cancer [excluded]
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Have Received chemotherapy ... for this disease
Cannot have received: endocrine therapy
Have Received ... endocrine therapy ... for this disease
Cannot have received: targeted therapy
Have Received ... targeted therapy ... for this disease
Cannot have received: radiation therapy
Have Received ... radiation therapy ... for this disease
Cannot have received: anti-PD-1 therapy
Received treatment with anti-PD-1, anti-PDL1, anti-PD-L2 drugs, or other immunotherapy
Cannot have received: anti-PD-L1 therapy
Received treatment with anti-PD-1, anti-PDL1, anti-PD-L2 drugs, or other immunotherapy
Cannot have received: anti-PD-L2 therapy
Received treatment with anti-PD-1, anti-PDL1, anti-PD-L2 drugs, or other immunotherapy
Cannot have received: checkpoint inhibitor
Received treatment with anti-PD-1, anti-PDL1, anti-PD-L2 drugs, or other immunotherapy
Lab requirements
Blood counts
absolute value of neutrophil count ≥ 2.0 × 10^9/l; hemoglobin ≥ 100g/l; platelet count ≥ 100 × 10^9/l
Kidney function
creatinine <1.5 × uln
Liver function
total bilirubin <1.5 uln; ast/alt < 1.5×uln
Cardiac function
cardiac ultrasound ef value ≥ 55%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify